Related Experiment Video
Updated: May 30, 2025

En Face Detection of Nitric Oxide and Superoxide in Endothelial Layer of Intact Arteries
Published on: February 25, 2016
Decreased nitric oxide production is a novel therapeutic target for salt-induced nocturnal polyuria in aging
Takahiro Imanaka1, Kentaro Takezawa2, Yuma Kujime1
1Department of Urology, Osaka University Graduate School of Medicine, 2-2, Yamadaoka, Suita-city, 565-0871, Osaka, Japan.
Abstract:
Nocturnal polyuria is a major cause of nocturia, which affects quality of life. Aging-related decreases in nitric oxide production have been reported to contribute to salt-induced nocturnal polyuria. We posited that enhanced nitric oxide production from exercise could mitigate salt-induced nocturnal polyuria. To validate, we assessed the impact of 4 weeks of moderate-intensity exercise on intrarenal renin-angiotensin system activity and salt-induced polyuria during inactive periods in 80-week-old mice. The moderate-intensity exercise group (Mod-Ex) had increased nitric oxide production and suppressed intrarenal renin-angiotensin system compared to the sedentary group (Sed) (renal angiotensinogen level: Sed vs. Mod-Ex, 1.101 ± 0.077 vs. 0.630 ± 0.048 arbitrary unit, P = 0.002). This exercise also alleviated salt-induced polyuria during inactive periods (diurnal polyuria index: Sed vs. Mod-Ex, 0.292 ± 0.027 vs. 0.193 ± 0.023, P = 0.018). These effects were neutralized by suppression of nitric oxide production by oral administration of Nω-Nitro-L-arginine methyl ester hydrochloride, an nitric oxide synthesis inhibitor. These findings indicate that exercise-induced improvements in salt-induced polyuria during inactive periods are caused by increases in nitric oxide production. In summary, increasing nitric oxide production may serve as a treatment method for salt-induced nocturnal polyuria in older adults.
More Related Videos
Related Concept Videos
Antihypertensive Drugs: Vasodilators
Nitric Oxide Signaling Pathway
Antihypertensive Drugs: Action of Diuretics
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antihypertensive Drugs: Potassium-Sparing Diuretics

